In Vivo Evaluation of 1-O-(4-(2-Fluoroethyl-Carbamoyloxymethyl)-2-Nitrophenyl)-O-beta-D-Glucopyronuronate: A Positron Emission Tomographic Tracer for Imaging beta-Glucuronidase Activity in a Tumor/Inflammation Rodent ModelFarinha Antunes, I., Haisma, H. J., Elsinga, P. H., van Waarde, A., Willemsen, A. T. M., Dierckx, R. A. & de Vries, E. F. J., 2012, In : Molecular imaging. 11, 1, p. 77-87 11 p.
Research output: Contribution to journal › Article › Academic › peer-review
beta-Glucuronidase (beta-GUS) plays an important role in inflammation and degenerative processes. The enzyme has also been investigated as a target in prodrug therapy for cancer. To investigate the role of beta-GUS in pathologies and to optimize beta-GUS-based prodrug therapies, we recently developed a positron emission tomographic (PET) tracer, 1-O-(4-(2-fluoroethyl-carbamoyloxymethyl)-2-nitrophenyl)-O-beta-D-glucopyronuronate ([F-18]FEAnGA), which proved to be selectively cleaved by beta-GUS. Here we present the in vivo evaluation of [F-18]FEAnGA for imaging of beta-GUS in a tumor/inflammation model. Ex vivo biodistribution of [F-18]FEAnGA was conducted in healthy rats. PET imaging and pharmacokinetic modeling were performed in Wistar rats bearing C6 tumors of different sizes and sterile inflammation. The biodistribution studies of [F-18]FEAnGA indicated low uptake in major organs and rapid excretion through the renal pathway. MicroPET studies revealed three times higher uptake in the viable part of larger C6 gliomas than in smaller C6 gliomas. Uptake in inflamed muscle was significantly higher than in control muscle. The distribution volume of [F-18]FEAnGA in the viable part of the tumor correlated well with the cleavage of the tracer to [F-18]fluoroethylamine and the spacer 4-hydroxy-3-nitrobenzyl alcohol. [F-18]FEAnGA is a PET tracer able to detect increased activity of beta-GUS in large solid tumors and in inflamed tissues.
|Number of pages||11|
|Publication status||Published - 2012|
- TUMOR, PRODRUG, PET, EXPRESSION, EFFICACY, MONOTHERAPY, ACTIVATION, CANCER, LIVER